Selling, General, and Administrative Costs: Amgen Inc. vs Jazz Pharmaceuticals plc

A Tale of Two Biopharma Giants: Amgen Inc. vs Jazz Pharmaceuticals plc

In the competitive landscape of biopharmaceuticals, understanding operational costs is crucial. Over the past decade, Amgen Inc. and Jazz Pharmaceuticals plc have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amgen's SG&A costs have surged by approximately 31%, peaking in 2023. In contrast, Jazz Pharmaceuticals experienced a more dramatic increase of around 231% during the same period, with a notable spike in 2021. This divergence highlights Amgen's steady growth strategy compared to Jazz's aggressive expansion. The data underscores the importance of strategic financial management in the biopharma sector, where operational efficiency can significantly impact market positioning. As these companies continue to evolve, their SG&A trends offer valuable insights into their business strategies and market dynamics.